Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 10/20 | 0.61 |
| ▸ | BCHE | P06276 | 7/20 | 0.61 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.61 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.61 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.50 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31139202 | 0.97 | ACHE (0.58) | ACHEBCHECHRM1EPHX2GRIN1 | |
| SCHEMBL4276722 | 0.94 | ACHE (0.60) | ACHEBCHECHRM1EPHX2 | |
| SCHEMBL4271348 | 0.93 | ACHE (0.59) | ACHEBCHECHRM1EPHX2 | |
| SCHEMBL4267672 | 0.92 | BCHE (0.58) | ACHEBCHECHRM1EPHX2 | |
| SCHEMBL4274740 | 0.92 | BCHE (0.58) | ACHEBCHECHRM1EPHX2 | |
| SCHEMBL4280010 | 0.92 | BCHE (0.58) | ACHEBCHECHRM1EPHX2 | |
| SCHEMBL4270443 | 0.92 | BCHE (0.58) | ACHEBCHECHRM1EPHX2 | |
| SCHEMBL4280053 | 0.92 | BCHE (0.58) | ACHEBCHECHRM1EPHX2 | |
| SCHEMBL4268755 | 0.92 | BCHE (0.58) | ACHEBCHECHRM1EPHX2 | |
| SCHEMBL31139204 | 0.91 | ACHE (0.63) | ACHEBCHECHRM1EPHX2GRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118724871-B | Pyrazolone-tacrine compound and preparation method and application thereof | 安徽中医药大学 | 2025-01-28 | — | — | CN | disclosed |
| CN-118724871-A | Pyrazolone-tacrine compound and preparation method and application thereof | 安徽中医药大学 | 2024-10-01 | — | — | CN | disclosed |
| US-7605265-B2 | Heterodimers and methods of using them | Biotechnology Research Corporation Ltd. (CN) | 2009-10-20 | — | — | US | disclosed |
| WO-2008091901-A1 | HETERODIMERS AND METHODS OF USING THEM | BIOTECHNOLOGY RESEARCH CORPORATION LIMITED (CN) | 2008-07-31 | — | — | WO | disclosed |
| US-20080176308-A1 | Heterodimers and Methods of Using Them | BIOTECHNOLOGY RESEARCH CORPORATION LIMITED (CN) | 2008-07-24 | — | — | US | disclosed |
| US-20070299093-A1 | Organic Compounds Useful for the Treatment of Alzheimer's Disease, Their Use and Method of Preparation | Alma Mater Studiorum-Universitá Di Bologna (IT) | 2007-12-27 | — | — | US | disclosed |
| US-7307083-B2 | Tetrahydro-acridine and dithiolane derivatives | ALMA MATER STUDIORUM-UNIVERSITA'DI BOLOGNA (IT) | 2007-12-11 | — | — | US | disclosed |
| US-20070219241-A1 | Organic Compounds Useful For The Treatment Of Alzheimer's Disease, Their Use And Method Of Preparation | ALMA MATER STUDIORUM-UNIVERSITA'DI BOLOGNA (IT) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219241-A1 | Organic Compounds Useful For The Treatment Of Alzheimer's Disease, Their Use And Method Of Preparation | OTC, PSEN2, PSEN1 | ACHE 5/4885BCHE 7/4885CHRM1 267/4885 |
| US-20070299093-A1 | Organic Compounds Useful for the Treatment of Alzheimer's Disease, Their Use and Method of Preparation | OTC, PSEN2, PSEN1 | ACHE 5/4885BCHE 7/4885CHRM1 267/4885 |
| US-20080176308-A1 | Heterodimers and Methods of Using Them | GRIN2A, GRIN3A, GRIN1 | ACHE 93/4885BCHE 47/4885CHRM1 860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.